ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

HN Sweat Gland Adenocarcinoma Rare, But Locally Aggressive

by Samara E. Kuehne • December 6, 2017

  • Tweet
  • Email
Print-Friendly Version

What are the demographics and clinicopathologic traits of head and neck sweat gland adenocarcinoma (HNSGA), and what are the poor prognostic indicators?

Bottom line
HNSGA are locally aggressive tumors that most commonly occur on the face. Although regional and distant disease are rare on presentation, their presence predicts poorer outcomes. Other negative prognostic factors include older age, scalp and neck location, and histologically high-grade tumors.

You Might Also Like

  • PET-CT Adds to Management of Salivary Gland Malignancies
  • Gland-Preserving Approach to Chronic Sialadienitis Has Successful Outcomes
  • Salivary Gland Malignancies: Diagnosis and Treatment of a Rare and Challenging Cancer
  • Incidence of Adenocarcinoma Among Patients with Barrett’s Esophagus
Explore This Issue
December 2017

Background: The literature on HNSGA is limited. Sweat gland adenocarcinoma (SGA) is a rare adnexal tumor that most commonly arises in the palms and soles, and historically has been difficult to study due to the limited cases available in the literature, as well as the challenge in classifying this heterogeneous group of tumors. SGA usually begins as a painless red or violet papule that gradually progresses to a solid infiltrating nodule. SGA can spread via the lymphatics; common sites of distant metastases include liver, lung, and bone. The treatment of choice is wide surgical excision, with regional lymph node dissection when there is nodal metastasis. The efficacy of adjuvant chemotherapy and radiotherapy is controversial.

Study design: Retrospective population-based analysis.

Synopsis: Using the Surveillance, Epidemiology, and End Results registry from 2000 to 2013, the authors identified 627 cases of HNSGA. Data were analyzed for incidence trends, demographic and clinicopathologic traits, and predictors of disease-specific survival (DSS). The majority of HNSGA cases were white, male, and 60 to 79 years old. The incidence was 0.036 per 100,000 people. Tumors most often presented as localized disease and histological grade II/III. The skin of the face was the most common primary site (43.4%), followed by the scalp and neck (31.6%). Overall 5-, 10-, and 20-year DSS were 94.6%, 89.6%, and 79.8%, respectively. Ethnicity did not affect survival, whereas a younger age at diagnosis and female sex conferred an advantage at 10 years and five years, respectively. The origin of the HNSGA (apocrine vs. eccrine) did not affect outcomes. Regional and distant disease predicted worse DSS at five, 10, and 20 years. Compared with grade I/II disease, grade III/IV dramatically worsened five-, 10-, and 20-year DSS. Scalp and neck HNSGA exhibited the poorest 20-year DSS compared with other primary sites.

This analysis suggests that HNSGA typically is identified early in its progression and mostly appears to be locally aggressive in behavior. Although there is no established algorithm for the treatment of SGA, there is general consensus in the literature that primary surgical excision with wide margins (1 cm–2 cm) and therapeutic neck dissection in the presence of clinically positive nodes is the recommended treatment.

Pages: 1 2 | Single Page

Filed Under: Head and Neck, Literature Reviews Tagged With: clinical care, HNSGA, SGA, sweat gland adenocarcinomaIssue: December 2017

You Might Also Like:

  • PET-CT Adds to Management of Salivary Gland Malignancies
  • Gland-Preserving Approach to Chronic Sialadienitis Has Successful Outcomes
  • Salivary Gland Malignancies: Diagnosis and Treatment of a Rare and Challenging Cancer
  • Incidence of Adenocarcinoma Among Patients with Barrett’s Esophagus

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Otolaryngologists Have a Major Role to Play in Treating COVID-19 Long-Haulers
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Podcasts Becoming More Popular Method of Education for Otolaryngologists
    • How to Embrace Optimism in the Midst of the COVID-19 Pandemic
    • Tips on How to Approach Conversations with Patients about the COVID-19 Vaccine
    • Steps You Should Take to Protect Your Voice and Hearing During Telemedicine Sessions
    • Routine Postoperative Adjunct Treatments Unnecessary for Idiopathic Cerebrospinal Fluid Leaks

Polls

Have you spoken with your patients about receiving the COVID-19 vaccine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.